Drug Profile
Timapiprant - Atopix Therapeutics
Alternative Names: CHF 6532; OC 459; OC-000459; ODC-9101Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Oxagen
- Developer Atopix Therapeutics; Chiesi Farmaceutici; Oxagen
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Indoles; Quinolines; Skin disorder therapies; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma
- Phase II Allergic rhinitis; Allergic rhinoconjunctivitis; Atopic dermatitis
- Discontinued Eosinophilic oesophagitis
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Belgium (PO, Tablet)
- 28 Sep 2021 Phase-III clinical trials in Asthma in USA (PO) before September 2021 (Chiesi Farmaceutici's pipeline, September 2021)
- 05 Sep 2021 Chiesi Farmaceutici discontinues a phase-III trials in Asthma (In children, In adolescents, In adults, In the elderly) in Poland, Greece, Bulgaria, Germany, Hungary, Czech Republic, France and Italy (PO) (EudraCT2018-003548-22) (NCT04049175)